ArticleImmunity2026
Positioning and reversible suppression of CCR7
Abstract read
In one paragraph
Article in Immunity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Dendritic cell PD-L2 restrains intratumoral CD8bioRxiv : the preprint server for biology · 2026Article
- Cell Membrane-Engineered FePDA Nanoparticles Integrate Ferroptosis and Antitumor Immunity.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting.Acta pharmacologica Sinica · 2026Review
- Type 2 conventional dendritic cells and regulatory T cells form a barrier tissue circuit to control allergic inflammation.bioRxiv : the preprint server for biology · 2026Article
- Structural Determinants and Repair of Membrane Microdomains in Dendritic Cell-Mediated Antitumor Immunity: An Integrative Mechanistic Synthesis.International journal of molecular sciences · 2026Review
- Single-cell omics in tumor lymph node metastasis: mechanisms and therapeutic implications.Molecular cancer · 2026Review
- Mechanical properties of the tumor microenvironment: drivers of immunotherapy resistance in solid tumors.Frontiers in immunology · 2026Review
- Beyond the tumor microenvironment: a hierarchical immune-circuit model of immune checkpoint blockade resistance.Frontiers in oncology · 2026Review
- Regulatory T cells in breast cancer drivers of immune suppression and targets for immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
45 authors.
Beatrice ZittiDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Florent DuvalDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Pratyaksha WirapatiDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Mehdi HichamDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Yuxuan XieDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Juhyun OhCenter for Systems Biology, Massachusetts General Brigham and Harvard Medical School, Boston, MA, USA.
Jan HoelzlCenter for Systems Biology, Massachusetts General Brigham and Harvard Medical School, Boston, MA, USA; Department of Medical Oncology, Heidelberg University Hospital, Heidelberg, Germany.
Philippa MeiserInstitute of Molecular Immunology, TUM University Hospital, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany.
Marco VarroneAGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Hannah M PetersonCenter for Systems Biology, Massachusetts General Brigham and Harvard Medical School, Boston, MA, USA.
Chiara CianciarusoDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Ruben BillDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Felix BayerlDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Evangelia BolliDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Anne-Gaëlle GoubetDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Máté KissDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Sheri McDowellDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Phil ChengAGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Dan CelestiniAGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Julie TerzicDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Thomas ZwahlenDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland.
Nagham AloucheDepartment of Immunobiology, University of Lausanne, Lausanne, Switzerland.
Nawel ZouggariDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland.
David TarussioDepartment of Oncology, Center for Experimental Therapeutics, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Stephanie TissotDepartment of Oncology, Center for Experimental Therapeutics, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Paula Nunes-HaslerDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Michael LanutiDivision of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, USA.
William C FaquinDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Peter M SadowDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA; Department of Otolaryngology, Massachusetts Eye and Ear, Harvard Medical School, Boston, MA, USA.
Jean-Christophe TilleDivision of Clinical Pathology, Geneva University Hospitals, Geneva, Switzerland.
Sana Intidhar Labidi-GalyDepartment of Oncology, Geneva University Hospital, Geneva, Switzerland.
Christopher S GarrisCenter for Systems Biology, Massachusetts General Brigham and Harvard Medical School, Boston, MA, USA; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Stephanie HuguesDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland.
Tatiana V PetrovaDepartment of Oncology, University of Lausanne, Lausanne, Switzerland; Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Burkhard LudewigInstitute of Immunobiology, Cantonal Hospital, St. Gallen, Switzerland; University Heart Center, University Hospital Zurich, Zurich, Switzerland; Center for Translational and Experimental Cardiology, University Hospital Zurich, Zurich, Switzerland.
Sergio QuezadaCancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, London, UK.
Sanjiv LutherDepartment of Immunobiology, University of Lausanne, Lausanne, Switzerland.
Thorsten R MempelCenter for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, USA.
Giovanni CirielloAGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Department of Computational Biology, University of Lausanne, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Sara I PaiDepartment of Surgery, Yale University School of Medicine, New Haven, CT, USA.
Olivier MichielinAGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Swiss Institute of Bioinformatics, Lausanne, Switzerland; Department of Oncology, Geneva University Hospital, Geneva, Switzerland.
Jan P BöttcherInstitute of Molecular Immunology, TUM University Hospital, School of Medicine and Health, Technical University of Munich (TUM), Munich, Germany; Department of Experimental Immunology, Institute of Immunology, University of Tübingen, Tübingen, Germany; M3 Research Center, University Hospital Tübingen, University of Tübingen, Tübingen, Germany.
Ralph WeisslederCenter for Systems Biology, Massachusetts General Brigham and Harvard Medical School, Boston, MA, USA; Department of Systems Biology, Harvard Medical School, Boston, MA, USA; Department of Radiology, Massachusetts General Hospital, and Harvard Medical School, Boston, MA, USA.
Mikael J PittetDepartment of Pathology and Immunology, and Center for Translational Oncohaematology Research, University of Geneva, Geneva, Switzerland; AGORA Cancer Research Center, and Swiss Cancer Center Leman, Lausanne, Switzerland; Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Ludwig Institute for Cancer Research, Lausanne, Switzerland. Electronic address: mikael.pittet@unige.ch.
Funding
Strategies to Overcome Immune Resistance in Head and Neck CancersP01CA240239 · NCI · YALE UNIVERSITY · PI PAI, SARA ISABEL · 2019 to 2023
$8.4MCellular mechanisms by which exhausted T cell responses are restoredR01AI123349 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI Thorsten Roman Mempel · 2017 to 2026
$4.5MEarly detection and risk of head and neck cancer through immune based spatial omicsU01DE033324 · NIDCR · YALE UNIVERSITY · PI Sara Isabel Pai · 2023 to 2026
$2.7MA mechanism to minimize auto-reactivity in the tissue-resident memory T cell poolR01AI163223 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI MEMPEL, THORSTEN ROMAN · 2021 to 2025
$2.4MCue-101 and TCR-T cell Combinatorial Strategy for HPV+ Head and Neck CancersR01CA278212 · NCI · YALE UNIVERSITY · PI Sara Isabel Pai · 2024 to 2026
$2.0MBioorthogonal probe development for highly parallel in vivo imagingR33CA277820 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2023 to 2025
$1.2MNCI NIH HHS P01 CA240239NCI NIH HHS R01 CA278212NCI NIH HHS R33 CA277820NIAID NIH HHS R01 AI123349NIAID NIH HHS R01 AI163223NIDCR NIH HHS U01 DE033324
Abstract
Tumor-resident CCR7
Indexed as
Dendritic CellsNeoplasmsReceptors, CCR7AnimalsCD40 AntigensCD8-Positive T-LymphocytesCell CommunicationChemokine CCL19HumansLymphocyte ActivationMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryTumor MicroenvironmentCCR7 protein, humanCcr7 protein, mouseCD40 AntigensChemokine CCL19Receptors, CCR7cancer immunitycancer immunity cyclechemokinesdendritic cellsimmunotherapyregulatoryT cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.